A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Esophageal Cancer|Gastric Adenocarcinoma|HER2 Gene Mutation
DRUG: Pembrolizumab|DRUG: Trastuzumab|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: 5-Fluorouracil|DRUG: Docetaxel
Event-free survival (EFS), EFS is defined as the time from start of treatment to time of disease progression, recurrence, or death, whichever occurs first., 2 years
Eligible patients will receive 8 peri-operative cycles of pembrolizumab and trastuzumab with chemotherapy (fluoropyrimidine/oxaliplatin doublet for patients initially enrolled and subsequently FLOT \[5-fluorouracil, oxaliplatin and docetaxel\] followed by pembrolizumab and trastuzumab maintenance to complete 1 total year of therapy.